Conference Day Two - Thursday | April 18, 2024
8:00 am Morning Refreshments
8:25 am Chair’s Opening Remarks
Antibodies Ahead of the Curve: Developing Antibody Target Engagement & Fc-Mediated Function
8:30 am Biology-Guided Engineering of Antibody & Albumin Molecules
Synopsis
- FcRn as a key homeostatic regulator of both IgG and albumin
- Why considering large cross-species FcRn binding differences
- Engineering of antibody and albumin formats with tailored binding and transport properties
- Modulating transplacental transport of antibody and albumin designs
9:00 am Functional Evaluation of mAb Fc Modifications Dependent on In Vitro Incorporation of Physiological Relevant Variables – Enhancing Design Optimization
Synopsis
- Influence of antibody target/epitope on the functional outcome of Fc engineering strategies
- Importance of relevant factors (e.g. antigen binding, competing IgG) during the assessment of Fc engineering strategies
- Translatability of human Fc engineering strategies to murine and cynomolgus Fc receptors
9:30 am Fc Silencing: How Much Silencing do we Really Need?
Synopsis
- Determining IgG FcyRs binding and signalling profiles by cell-based assay
- Evaluating the main Fc silencing mutations
- What the specific needs are for silencing and how to understand the residual binding on FcgRs
- Discussing FcR binding or silencing in vivo and biologics efficacy
10:00 am Severing Fc Effector Functions from Antigen Binding; IgG Proteases for Autoimmunity
Synopsis
- Discussing bacterial IgG protease IdeS cleaving antibodies in the hinge to decouple effector functions from antigen binding
- AI-guided removal of T cell epitopes and shielding of surface epitopes by glycoengineering to reduce Immunogenicity of IdeS
- Extending pharmacodynamics by hyperglycosylation, creating a long-lived deimmunized IgG protease for deactivation and depletion of IgG autoantibodies
10:30 am Morning Break & Networking
11:30 am Round table Discussions: Join Peer-Led Group Discussions to Crowdsource Insights and Enhance the Therapeutic Potency of Fc-Mediated Function
Strategies to Tailor the PK of Biologics, with or without Effector Functions
Diversified FcR Interactions for Future Flexibility in Antibody Engineering
12:00 pm Antibody Ideas & Evolution: Surveying Interactions, Receptor Activity Modulation, & Drug Development
Synopsis
- Attaining better in-depth biological understanding to keep up with antibody evolution, and progress beyond assumptions towards a more comprehensive analysis of antibody functions
- Looking at how to modify antibody architecture to adapt it based on cellular interactions, heightening antibody design, binding, and half-life extension
- Expanding the design space of antibodies to modulate receptor activity and diversify application to achieve flexibility in antibody engineering
1:00 pm Lunch & Networking
Targeting FcyR in its Own Right – What is the Next Mutation?
2:00 pm “All Things Fc Gamma”: Harnessing the Potential of Fc Gamma Receptors to Tune Antibody-based Immunotherapy
Synopsis
- Examining the beneficial or compromising effect of FcyRs in antibody-based cancer immunotherapies
- Tailored FcgR-blockade to enhance the efficacy of therapeutic antibodies
- Outlook inflammation – how FcgRs can be harnessed for the treatment of autoimmune and inflammatory disease
2:30 pm Unlocking Fc Gamma Receptors’ Power: Fine-Tuning Antibody-Based Immunotherapy Identification & Characterization of FcγRIIb Selective PD-1 Agonist mAbs
Synopsis
- Agonist antibodies to PD-1 that mimic the function of natural ligands have the potential to suppress human autoimmune diseases and reinstate tolerance
- PD-1 agonist antibodies rely on the mediated clustering of Fc-gamma receptors (FcγRs) to elicit their suppressive function
- Seismic PD-1 agonist is a dual-cell bidirectional antibody that agonizes PD-1 and selectively binds the inhibitory FcγRIIb receptor
- Seismic PD-1 agonist inhibits T-cell activity while preventing antigen presenting cell activation